Related Experiment Video
Updated: Jul 5, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas
Abstract:
Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) family of cytokines, and binds to the OSM receptor (OSMR) to inhibit cancer growth. Four forms of OSMR have been identified: leukemia inhibitory factor receptor (LIFR), OSMR beta, short-form OSMR (OSMRs) and soluble OSMR (sOSMR). In this study, we examined the type and expression of OSMR in lung adenocarcinomas (LADCs). Expression of OSMR was determined by reverse transcription-polymerase chain reaction (RT-PCR), immunoblotting, immunohistochemistry and confocal immunofluorescent microscopy (CIM). Our results showed that, among the four forms of OSMR, OSMRs was mainly expressed in LADC, and expression level of OSMRs correlated with patient survival. CIM revealed that OSMRs was localized on the cell membrane of LADC cell lines in vitro. OSMRs acts as a decoy receptor by reducing the inhibitory effect of OSM on cell growth. Decrease in OSMRs expression by siRNA increased cell sensitivity to OSM, and ectopic expression of OSMRs reduced cell sensitivity to OSM. These results suggest that expression of OSMRs, which operates as a decoy receptor for OSM, is correlated with disease progression and adverse prognosis in patients with LADC.
Insights
Short-form Oncostatin M receptor (OSMRs) is mainly expressed in lung adenocarcinomas (LADCs) and acts as a decoy receptor. Its expression correlates with patient survival, suggesting a role in LADC progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Oncostatin M (OSM) is an IL-6 family cytokine that inhibits cancer growth via its receptor (OSMR).
- Four OSMR forms exist: LIFR, OSMR beta, OSMRs, and sOSMR.
- The role of specific OSMR forms in lung adenocarcinoma (LADC) is not well understood.
Purpose of the Study:
- To investigate the type and expression of OSMR in LADC.
- To determine the functional role of OSMRs in LADC cell growth and OSM signaling.
- To correlate OSMRs expression with patient prognosis.
Main Methods:
- Reverse transcription-polymerase chain reaction (RT-PCR) for gene expression.
- Immunoblotting and immunohistochemistry for protein detection.
- Confocal immunofluorescent microscopy (CIM) for cellular localization.
- siRNA for gene silencing and ectopic expression for functional studies.
Main Results:
- OSMRs was the predominant OSMR form expressed in LADC.
- OSMRs localized to the cell membrane of LADC cells.
- OSMRs expression levels correlated significantly with patient survival.
- OSMRs functioned as a decoy receptor, reducing OSM's inhibitory effect on cell growth.
- Modulating OSMRs expression altered LADC cell sensitivity to OSM.
Conclusions:
- OSMRs is a key mediator in LADC, acting as a decoy receptor for OSM.
- OSMRs expression is linked to disease progression and poorer prognosis in LADC patients.
- Targeting OSMRs may offer a therapeutic strategy for LADC.
